TW492876B - New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture - Google Patents
New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture Download PDFInfo
- Publication number
- TW492876B TW492876B TW084108225A TW84108225A TW492876B TW 492876 B TW492876 B TW 492876B TW 084108225 A TW084108225 A TW 084108225A TW 84108225 A TW84108225 A TW 84108225A TW 492876 B TW492876 B TW 492876B
- Authority
- TW
- Taiwan
- Prior art keywords
- cyclosporine
- pharmaceutical composition
- item
- weight
- patent scope
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 33
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 32
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 23
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 4
- 239000002552 dosage form Substances 0.000 title description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 4
- 229930195729 fatty acid Natural products 0.000 claims abstract description 4
- 239000000194 fatty acid Substances 0.000 claims abstract description 4
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims abstract description 3
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 108010019249 cyclosporin G Proteins 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000002334 glycols Chemical class 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- -1 polyethylene Polymers 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims 1
- 241000219823 Medicago Species 0.000 claims 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- SPRAXCMVHXBDMZ-UHFFFAOYSA-N Cyclosporin X Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O SPRAXCMVHXBDMZ-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Description
492876 A7 _B7 _ 五、發明說明(/ ) / …一 本發阴係關於環孢靈,特別是環孢靈A ,對於口服施 周所包含的液體配方。 環孢靈是由徵生耢所產生之天然的環狀胜M e 環®靈 中最重要的代表是環孢靈A ,它被用在擷制器官排斥的移 植治療和骨髓移植上。環孢靈A的徵生®產物及分離和純 化至非结晶無色粉末,其本質上已在德國專利案24 5 Γ— Ο Γ-* ΓΛ r+t +FT .
ο ο o ^ m m :J 環抱靈A 越來越多被周在自體免疫疾病的處理上 5 例牛皮癖(P s 〇 r i a s i s), 葡萄膜炎(u n e i t i s ), 賢病變症 候群(nephrotic syndronOM 及其飽 0 環孢靈的抗發炎及抗寄生蟲的特性也被描逑。 因為環孢靈疏水性的特性,要產生造戚此活性成份高 度生物可利周性的製藥組成是很困難的。實際上,已知的 _量型式顯示S在藥理動力學變數上招當廣的儒體肉和假 體間變異t生·。在招同的謂量時,Μ疲内環31靈的量在不同 病入閭的變異可達到5 0 %。即使在一儷相同的病人内其 吸牧量的變異&很大c但是,免疫抑制的治療依賴在爾量 依賴副作周和移植器官排斥之間相當窄的治療窗中。 不好的生物利羯搜乃特別歸因於環孢靈在包含水的颚 量形式混合物中的低溶解度。 有很多入企圖去解決這些製藥上的問題。 已知且商業上可提供的謂量形式為親脂性和親水性溶 麵的複雜条統和可溶的清潔劑,並帶有溶解環孢靈和保持 本纸張尺度適周中國國家標準(CNS)A4規格(210 X 297公釐〉 (請先閱讀背面之注意事項再填寫本頁)
492876 A7 B7 五、發明說明( V)
它們在 />α «-Ρ· ΛΛτ* m m w i工片ii ^ 丢 m 33 I h rr: uj 4j ,ΨΛττ .^ i± W M '^u t. i XL m icK bL ^ ...哗 迫 v ~m 其 m 旦 rf-l· i±± J^L itu pq α τ ±n ±± tJl ΕΕί -4-ft-i CD -£?p iJll用安S iB 式包含 A VT 3* O Si表面 mae ^i_ 4-ί<κ·. m jb m rriiri· & φ^4- 昭 J>C ί工 ίϊ*τ ί志 ·、.+ W f4C; i±. m m 3 8 8 3 ό 0 7顯不]史周油以反酒1¾ 媒介物。棍據lit專利寨,商業上可提 溶疲包含徹欖油,酒精和當作表面活 f i 1®。但是&配方會留下問題。 審通常有一令入不悅的氣祿和/或祿 不飽和脂詰酸的油容易腐敗c 的配方中須要相對之高含量的酒精。 對小孩施用此產品上會造成®難,並 這個目的而使用瑱充膠囊時,必須増 完成的精心工作。 案2 ,222 ,770的新頴劑量形 產品至溶液狀的途徑。這些系統包括 一有活性組成物,親脂性,親水性層 雜条統ϋ ifc形態的系統會造成交互反 所使羯的其中一種物質對病入衙言非 水溶液系統内的溶液中的目的。它們至少包含四個 ,名稱為活注組成物,植物油,酒精和一種表®活 國專利案4, -W- KA?衣占丨 /r*^* AtJ~r 六檢_连::¾ d li 飲羯的環孢靈 X 1 D ii L a d r a 表面活搜媒介 it之外,含有 -V, -T^ £rr Ziv 久,tt包3個 高酒精含量在 -fcr AAt RR 3¾ · 龅仔P li问邊 ϋ 為了避免蒸發 泡包装法包装 露在G Β專利 由微、?L跋觀&勺 個成份,形成 活性物質的複 的增加,Μ及 的危機之增加。 國專利案39 ,24,207掲露一生產施用靜腿 羯的樣疋水搭液m注射丨谷液之過程,其中 )Μ重量計一份的環孢靈 木紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -------*--------I 一 492876 A7 B7 五、發明說明(3 b ) K重量計8至1 3份的一或多種單詣飽和羥脂W 酸及聚乙二醇和 羥醇混合 ••it/· -r- tJ_ 1¾ 不叙土 m is ^ 讲乂 m ⑽河 所有 f 工本 r/j V 上小 在一起 產td和 破壞生 商業上 油,小 Μ及一或多種漬 計1至 _ fLL u i± Mi 研究。 鶴可利 -qpr Λθ 5:ιϊ 口」符ΐ·ϋ 麥油, :在7!挪 Ϊ ^Jrs 如C Y - -fr LL^ ϋ 之 ίχ: 士 人 £^¥3 t±^ ϋ: 一漶疋 的釋放特 用超音波 _行是圍 成_量形 tK傲 ;&為 口」 X、)上 2¾ a ) f^)-x rs -Tit? wj m m m b ) A ·/ V ri / A 製藥形 及徵· kxL· , i士 1± u ia 生成無 難的ύ 式是較 本發明 飲用溶 提及的 Μ重量 當作活 Μ重量 式是特 顆粒的 些形式 溶劑正 它同樣 不適合 驁奇的 疲或膠 hr 日 S ~zrf 问起KJ 計〇 * iOJL ί/\ Ί *± )136 m 計6至 3汾的 專利寨 為了周 OH .liL· · nj ι± -的劑量 玉米油 單或聚 a 及特別 別遺當 彤式並 戸 典 士入 w π < 菱形结 ί£顯示 的。 發現具 囊型式 Γ I Λ77 >j\ m m 5至2 1個或多個 和/或聚一 内能葰用來□服的製藥形式: 水稀釋這些配方,環孢靈沈 型式包括油性,親脂的組成 nja 單 …或二 羥醇類 甘油IS ) 0 5 4專利寨运明结晶xKj 是 CY-Α/Χ-ί I I , 的。這些配方說包含環孢靈 且有更好的穩定性或更良好 局部皮膚或局部眼睛使周。 晶形式的方法在企業層次上 無故定形式的環孢靈對於生 簡單組成和高生_可利用S 之□服施用的環孢靈劑量形 法,其包含: ,最好是1份的多個無晶形
5份的IS和的C (請先閱讀背面之注意事項再填寫本頁) 訂---- -線! 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 492876 A7 _B7 —…_ 五、發明說明(屮) ;-、 0至C 2 2 S脂肪駿之一或多種聚乙二醇單i旨;最好是S 0 L U T 0 L © HS 15,g[3 聚乙二醇一660 — 12-(證基)一硬脂酸酷, c ) K重量計 1 至3 ,最好是2份的一或多種單或多 羥醇當作共溶劑,最好是乙醇和丙二醇環孢靈的溶解度相 當地增加,特別是K水稀釋而維持著這些量特定的比例時 0 這遷不能正常迆被假定因為劑量型式使周脂肪酸的聚 乙二醉s§只當作疏水層和親水層間額外的溶解質。 因此所有入對於如tt的一種配方能顯示商業產品的生 物平衡大為驚訝(見上方)。 實際上,它無法預言如此的一個簡單而無親脂成汾的 配方能夠達到茹tt高的生锪可利周性。 更進一*步發現M D服施用力式精羅地使用無晶形的 S靈,盈環孢靈含量大於5 %的配方,可造成相當好的溶 液特性,經水稀釋後仍能讓持為一穩定,清澈的溶液。 因此,本發明係關於口服劑量形式,為可飲用溶疲或 是包裝在膠囊内,均包括K下成份在K下的比例:
a) Μ重量計0 + 5至2 ,最好是1份的一或多個環 孢靈,特別是Μ無晶彩被使用的環孢靈Α或G fa ) Μ重量計6至9 ,最好是7 * 5份的飽和的C 1 0至C 2 2羥脂訪駿之一或多種聚乙二醇單酷;最好是S 0LUT0L® HS 15 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ^ ·ϋ 1 ·ϋ II 1-1 一 ov a n I n I m Λ/Μβ ϋ I n i r— — — — — — — 492876 A7 _B7 _ —_ 五、發明說明(/ ) C )以重量計1至3 ,最好是2份的一或多種覃或多 羥醇當作共溶劑,最好是乙醇和丙二醇 根:據本發明,在生產的過程中,必須小心量的比例要 讓持,並且環孢靈一開始即要在室溫下持續攪拌使之完全 溶解於酒精内,隨後在仍為室溫攪择下SO入丙二醇和S 〇丨u t ο 1⑬ H S 1 5。過程產生的溶液包含 每毫升1 0 0毫克的活性成份。K可歆周溶疲或膠囊形 式完成是在一已知的影式下進行,例5D在每個膠囊肉包含 100毫克,50毫克或25毫克的活性組成物。 棍據本發明之組成的生產在下面實洌中詳IS說明 : 袖:/£;ϊϊ 1 1 0 0公克非固定形式的環孢靈A在室溫下S浮而溶 於1 27毫升的酒精内。隨後,進一步再於室溫下攪拌, 加入9 6毫升的丙二醇。得到一環孢靈A清激溶液之後, 入7 5 0公克的S o i u t o i ® H S 1 5並進一 步攪拌。可得到一澄漬、黏稠包含每毫升1 00毫克環孢 靈A的溶液。 在實例1中所升成的環孢靈A溶液甩水Ml :40的 比例稀釋。所彤成的溶疲可維持數個月的漬澈和穩定。 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ▼-------訂-------·!線!
Claims (1)
- 492876 -, A8 ; ' Ί :. B8 :/.、 入C8 、 D8 — —— ~— f ' 七、申請專利範圍 丨乂Γ ^, (請先閲讀背面之注意事項再填寫本頁) 1 * 一種□服環ίΜ靈藥學組成物,其為哥飲用溶液或 ®囊影式,包含: a ) Μ重量計0 + 5至2份的一或多種無晶形環JS靈 當作活性成汾 D ) 从重量 §十 b 主 0 1方 u'j C 1 0 至匕 ε 2 證,§§ 3® 酸 《ί! 一或多種聚乙二醇單iS c) Μ重量計1至3份的一或多種翬或多羥醇當诈共 溶Si。 2 *根據帛請專利範圍第1項的藥擧組成物,使甩非 晶形環孢靈A或環孢靈G當作活性成份。 3 * —種製儀□跟環孢靈藥學組成物的方法,該藥學 組成物為可飲用溶疲或膠囊形式,苜先在室溫下攪拌 a) 每1 00公克無晶形環孢靈,溶於1 27毫升的 酒精内 b) 又當在室溫下攪拌時,加入96毫升的丙二醇, 隱後又於室溫下攪拌, c )加入750公克的聚乙二醇—660— 1 2 —( 羥基)-硬脂酸脂,成為一清澈,黏稠的環孢靈溶液,並 Μ已茹的方式裝Μ成為可飮用的溶液或是包裝成為膠囊。 4 +如串請專利範圍第1項之藥學組成物,其包含Μ 重量計1份之一或多種無晶形環孢靈。 5 ♦如Φ譆專利範圍第1項之藥學組成物,其包含Μ 7 . 5份之飽和C 1 0至C 2 2羥脂訪酸之一或多種聚乙二 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 492876 A8 B8 C8 D8 六、申請專利範圍 醇覃酯。 (請先閲讀背面之注意事項再填寫本頁) 6 ▲ 50串請專利範圍第1項之藥學組成物,其包含Μ 重量計2扮的一或多種單或多證醇。 7 ♦如串請專利範圍第1項之藥學組成物,其中C 1 0至C 2 2羥脂肪酸之一或多種聚乙二醇覃酯為聚乙二 醇一660—12— (羥基)—硬脂酸脂 8 *如Φ請專利範圍第1項之藥學組成物,其中輋或 多羥醇為乙醇及/或两二醇 9 * Φ請專利範圍第3項之的方法 5 其中無晶彩環 孢靈為環孢靈A。 1 〇 +如串請專利範圍第1項之藥學組成物,其為膠 ir.< —p. . m n> is, ^ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4438861 | 1994-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW492876B true TW492876B (en) | 2002-07-01 |
Family
ID=6532126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW084108225A TW492876B (en) | 1994-11-03 | 1995-08-08 | New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6486124B2 (zh) |
| EP (1) | EP0789580B1 (zh) |
| JP (1) | JP3833248B2 (zh) |
| KR (1) | KR970704464A (zh) |
| CN (1) | CN1121238C (zh) |
| AT (1) | ATE218359T1 (zh) |
| AU (1) | AU715165B2 (zh) |
| BG (1) | BG62955B1 (zh) |
| BR (1) | BR9509550A (zh) |
| CA (1) | CA2231404C (zh) |
| CZ (1) | CZ287806B6 (zh) |
| DE (2) | DE59510233D1 (zh) |
| DK (1) | DK0789580T3 (zh) |
| EE (1) | EE03425B1 (zh) |
| ES (1) | ES2177652T3 (zh) |
| FI (1) | FI118722B (zh) |
| HU (1) | HUT77283A (zh) |
| LT (1) | LT4306B (zh) |
| LV (1) | LV11884B (zh) |
| NO (1) | NO970741D0 (zh) |
| PL (1) | PL183579B1 (zh) |
| PT (1) | PT789580E (zh) |
| RU (1) | RU2158601C2 (zh) |
| SK (1) | SK164796A3 (zh) |
| TR (1) | TR199501361A2 (zh) |
| TW (1) | TW492876B (zh) |
| WO (1) | WO1996014079A1 (zh) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0789580B1 (de) | 1994-11-03 | 2002-06-05 | Novartis AG | Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung |
| US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| DE69632125T2 (de) * | 1995-08-25 | 2004-09-16 | Sangstat Medical Corp., Menlo Park | Orale cyclosporinformulierungen |
| DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| KR20000069900A (ko) * | 1997-01-30 | 2000-11-25 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 오일을 함유하지 않은 사이클로스포린 a 함유 제약 조성물 |
| AU762247B2 (en) * | 1997-01-30 | 2003-06-19 | Novartis Ag | Oil-free pharmaceutical compositions containing cyclosporin A |
| DE19821951A1 (de) * | 1998-05-15 | 1999-11-18 | Basf Ag | Cyclosporin-Zubereitungen |
| AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| NZ512599A (en) | 1998-12-30 | 2003-10-31 | Dexcel Ltd | Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5 |
| US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| US6506742B2 (en) | 1999-12-13 | 2003-01-14 | Ortho-Mcneil Pharmaceutical, Inc. | Soluble contraceptive liquid formulation |
| US7851444B2 (en) | 2002-12-02 | 2010-12-14 | Xenome Ltd. | χ-conotoxin peptides (-1) |
| WO2004050688A1 (en) | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| SE0301119D0 (sv) * | 2003-04-14 | 2003-04-14 | Astrazeneca Ab | New non-ionic surfactants for solubilizing poorly soluble molecules |
| CN102552917A (zh) | 2003-08-13 | 2012-07-11 | 比奥孔有限公司 | 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂 |
| US20050059583A1 (en) * | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| RU2272643C2 (ru) * | 2004-06-11 | 2006-03-27 | Маргарита Васильевна Бибикова | Высокоактивный кристаллический препарат циклоспорина а и способ его получения |
| US7151085B2 (en) | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
| US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
| JP2008535921A (ja) | 2005-04-12 | 2008-09-04 | エラン・ファルマ・インターナショナル・リミテッド | シクロスポリンを含むナノ粒子および放出調節された組成物 |
| US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
| US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
| US7501393B2 (en) * | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| AU2012339693B2 (en) * | 2011-11-15 | 2017-09-07 | Allergan, Inc. | Cyclosporine A Form 2 and method of making same |
| ES2791751T3 (es) * | 2011-11-15 | 2020-11-05 | Allergan Inc | Suspensiones de forma 2 de ciclosporina A |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| GB1171125A (en) | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
| US3813345A (en) | 1971-08-05 | 1974-05-28 | Vanguard Chem Co Inc | Method of producing microcolloidal aqueous emulsions of unsaturated organic compounds |
| US3954967A (en) | 1971-08-05 | 1976-05-04 | Vanguard Chemical Company, Inc. | Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds |
| DE2463138C2 (de) | 1973-12-06 | 1984-07-05 | Sandoz-Patent-GmbH, 7850 Lörrach | Das Antibiotikum Cyclosporin B (S 7481/F-2), seine Herstellung und Verwendung |
| US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
| US4117118A (en) | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
| US4146499A (en) | 1976-09-18 | 1979-03-27 | Rosano Henri L | Method for preparing microemulsions |
| JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
| CH636013A5 (en) | 1978-03-07 | 1983-05-13 | Sandoz Ag | More readily absorbable pharmaceutical composition |
| FI65914C (fi) | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| CH641356A5 (en) | 1979-02-27 | 1984-02-29 | Sandoz Ag | Pharmaceutical compositions containing cyclosporin |
| AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
| FR2502951B1 (fr) | 1981-04-06 | 1985-12-06 | Sandoz Sa | Compositions pharmaceutiques topiques sous forme d'une micro-emulsion |
| AU558155B2 (en) | 1982-02-01 | 1987-01-22 | Sandoz Ltd. | Treating multiple sclerosis with dihydro-cyclosporin d |
| DE3225706C2 (de) | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen |
| DE3235612A1 (de) | 1982-09-25 | 1984-03-29 | Bayer Ag, 5090 Leverkusen | Mikroemulsionen |
| DE3237814A1 (de) | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| DE3315805A1 (de) | 1983-04-30 | 1984-11-08 | Bayer Ag, 5090 Leverkusen | Wirkstoffzubereitungen |
| JPS6061535A (ja) | 1983-08-24 | 1985-04-09 | エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | 製薬学的組成物 |
| FR2553661B1 (fr) | 1983-10-19 | 1985-12-20 | Rhone Poulenc Sante | Nouvelles microemulsions pharmaceutiquement acceptables |
| DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
| US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| GB8903804D0 (en) | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| EP0170623B1 (en) | 1984-08-02 | 1990-11-28 | Sandoz Ag | Novel pharmaceutical use of (nva)2-cyclosporine |
| CH662944A5 (it) | 1984-10-18 | 1987-11-13 | Pier Luigi Prof Dr Luisi | Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione. |
| JPS61280435A (ja) | 1985-04-04 | 1986-12-11 | Kanji Takada | サイクロスポリン類のリンパ指向性製剤 |
| JPS61249918A (ja) | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | 点眼剤 |
| IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
| US5023271A (en) | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
| US4797272A (en) | 1985-11-15 | 1989-01-10 | Eli Lilly And Company | Water-in-oil microemulsions for cosmetic uses |
| SE457693B (sv) | 1986-07-01 | 1989-01-23 | Drilletten Ab | Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas |
| EP0256856A3 (en) | 1986-08-14 | 1989-01-11 | Synthetic Blood Corporation | A parenterally administrable composition |
| DE3629386A1 (de) | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
| DE3707711A1 (de) | 1987-03-11 | 1988-09-22 | Hoechst Ag | Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung |
| CA1301642C (en) | 1987-03-30 | 1992-05-26 | Howard Bernard Dawson | Chemical formulations |
| US4798823A (en) | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
| ATE95193T1 (de) | 1987-06-17 | 1993-10-15 | Sandoz Ag | Cyclosporine und deren benutzung als arzneimittel. |
| GB2206119B (en) | 1987-06-22 | 1990-10-31 | Merck & Co Inc | A new cyclosporin derivative with modified "8-amino acid" |
| US4835002A (en) | 1987-07-10 | 1989-05-30 | Wolf Peter A | Microemulsions of oil in water and alcohol |
| HU205010B (en) | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
| US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
| IL88076A (en) | 1987-10-28 | 1993-01-14 | Nippon Shinyaku Co Ltd | Fat emulsions as drug carriers |
| US4914188A (en) | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
| HU203564B (en) | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
| ES2033086T3 (es) | 1988-01-29 | 1993-03-01 | Sankyo Company Limited | Un procedimiento para la preparacion de una composicion farmaceutica. |
| CH679119A5 (zh) | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
| HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
| KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| CA1337397C (en) | 1988-09-29 | 1995-10-24 | Hideo Nakajima | Emulsified composition |
| BE1003578A4 (fr) | 1988-10-26 | 1992-04-28 | Sandoz Sa | Nouvelles compositions ophtalmiques a base d'une cyclosporine. |
| AU5157590A (en) | 1989-02-06 | 1990-08-24 | Abbott Laboratories | Pharmaceutical compositions for oral administration |
| BE1003009A5 (fr) | 1989-02-09 | 1991-10-22 | Sandoz Sa | Nouvelles compositions pharmaceutiques a base de cyclosporines. |
| US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
| US5177110A (en) | 1989-10-27 | 1993-01-05 | Ciba-Geigy Corporation | Injectable parasiticidal composition |
| HU207222B (en) | 1990-02-15 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing eyedrops containing primycin |
| US5260301A (en) | 1990-03-01 | 1993-11-09 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical solution containing FK-506 |
| HU208491B (en) | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
| GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| ES2168271T3 (es) | 1992-09-25 | 2002-06-16 | Novartis Ag | Composiciones farmaceuticas que contienen ciclosporinas. |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| IL111003A0 (en) | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
| KR0146671B1 (ko) * | 1994-02-25 | 1998-08-17 | 김충환 | 사이클로스포린-함유 분말 조성물 |
| EP0705601B1 (de) | 1994-10-04 | 2000-01-19 | LOMAPHARM Rudolf Lohmann GmbH KG Pharmazeutische Fabrik | Lösungen von Anthrachinonen zur parenteralen Applikation |
| EP0789580B1 (de) | 1994-11-03 | 2002-06-05 | Novartis AG | Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung |
-
1995
- 1995-07-19 EP EP95925707A patent/EP0789580B1/de not_active Expired - Lifetime
- 1995-07-19 DE DE59510233T patent/DE59510233D1/de not_active Expired - Fee Related
- 1995-07-19 KR KR1019970700361A patent/KR970704464A/ko not_active Ceased
- 1995-07-19 HU HU9702144A patent/HUT77283A/hu unknown
- 1995-07-19 EE EE9700112A patent/EE03425B1/xx not_active IP Right Cessation
- 1995-07-19 CA CA002231404A patent/CA2231404C/en not_active Expired - Fee Related
- 1995-07-19 WO PCT/DE1995/000951 patent/WO1996014079A1/de not_active Ceased
- 1995-07-19 BR BR9509550A patent/BR9509550A/pt not_active Application Discontinuation
- 1995-07-19 SK SK1647-96A patent/SK164796A3/sk unknown
- 1995-07-19 ES ES95925707T patent/ES2177652T3/es not_active Expired - Lifetime
- 1995-07-19 DK DK95925707T patent/DK0789580T3/da active
- 1995-07-19 PT PT95925707T patent/PT789580E/pt unknown
- 1995-07-19 AU AU29751/95A patent/AU715165B2/en not_active Ceased
- 1995-07-19 RU RU97108682/14A patent/RU2158601C2/ru active
- 1995-07-19 AT AT95925707T patent/ATE218359T1/de not_active IP Right Cessation
- 1995-07-19 JP JP51493496A patent/JP3833248B2/ja not_active Expired - Fee Related
- 1995-07-19 CN CN95196010A patent/CN1121238C/zh not_active Expired - Fee Related
- 1995-07-19 CZ CZ19963616A patent/CZ287806B6/cs not_active IP Right Cessation
- 1995-08-08 TW TW084108225A patent/TW492876B/zh active
- 1995-10-26 DE DE19539860A patent/DE19539860A1/de not_active Withdrawn
- 1995-11-02 TR TR95/01361A patent/TR199501361A2/xx unknown
-
1997
- 1997-01-06 BG BG101117A patent/BG62955B1/bg unknown
- 1997-01-09 LT LT97-002A patent/LT4306B/lt not_active IP Right Cessation
- 1997-02-14 FI FI970634A patent/FI118722B/fi active IP Right Grant
- 1997-02-18 NO NO970741A patent/NO970741D0/no not_active Application Discontinuation
- 1997-05-14 LV LVP-97-94A patent/LV11884B/lv unknown
-
1998
- 1998-03-09 PL PL95318560A patent/PL183579B1/pl unknown
-
2001
- 2001-10-17 US US09/981,929 patent/US6486124B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW492876B (en) | New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture | |
| TW205035B (zh) | ||
| JP4170386B2 (ja) | 疎水性薬剤の投与システム | |
| TWI243060B (en) | Dispersion formulations containing lipase inhibitors | |
| ES2226976T3 (es) | Formulaciones galenicas de fenofibrato y su procedimiento de obtencion. | |
| TW201114766A (en) | Pharmaceutical composition for a hepatitis C viral protease inhibitor | |
| MX2010013203A (es) | Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona. | |
| US4397835A (en) | Enterosoluble hard-capsulated medicaments | |
| JPH0640916A (ja) | ニコランジルの製薬的に安定な製剤 | |
| TW455491B (en) | Pharmaceutical composition for oral administration | |
| Sarojini et al. | Oral medicated jellies–a review | |
| CN101933910A (zh) | 一种甲钴胺软胶囊及其制备方法 | |
| WO2003101378A2 (en) | Pharmaceutical formulation in a drug delivery system and process for preparing the same | |
| WO2005007070A2 (en) | Stable pharmaceutical composition | |
| EP2036575B1 (en) | Pharmaceutical compositions for oral use for treating patients affected by obesity | |
| JP7335256B2 (ja) | シメチコン及びロペラミドのエマルションの医薬製剤 | |
| US7632853B2 (en) | Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof | |
| US20050175686A1 (en) | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule | |
| Vishwakarma et al. | Pharmaceutics–Practical Manual (According to the PCI new Syllabus as per ER-2020) D. Pharm-First year | |
| JPH07267875A (ja) | オーレオバシジン類の高濃度溶液製剤 | |
| KR20240057565A (ko) | 무메프랄을 함유하는 장내 유산균 증식 및 우울증 예방 또는 치료용 조성물 | |
| WO2014135965A1 (en) | Bismuth liquid filled hard capsules | |
| US20060217320A1 (en) | Soft gel formulations for saquinavir | |
| FR2790200A1 (fr) | Formulation stable contenant de la fumagilline | |
| JP2025511778A (ja) | 酸化マグネシウムを含む充填材組成物を有するソフトゲルカプセル |